NRAS G12D
|
Melanoma
|
NRAS G12D
|
Melanoma
|
HL-085 Sensitive: C3 – Early Trials
|
HL-085 Sensitive: C3 – Early Trials
|
NRAS G12D
|
CMML
|
NRAS G12D
|
CMML
|
trametinib Resistant: C4 – Case Studies
|
trametinib Resistant: C4 – Case Studies
|
NRAS G12D
|
NSCLC
|
NRAS G12D
|
NSCLC
|
bevacizumab + atezolizumab Sensitive: C4 – Case Studies
|
bevacizumab + atezolizumab Sensitive: C4 – Case Studies
|
NRAS G12D
|
Prostate Cancer
|
NRAS G12D
|
Prostate Cancer
|
BAY 1125976 Sensitive: D – Preclinical
|
BAY 1125976 Sensitive: D – Preclinical
|
NRAS G12D
|
ALL
|
NRAS G12D
|
ALL
|
U0126 Sensitive: D – Preclinical
|
U0126 Sensitive: D – Preclinical
|
NRAS G12D
|
AML
|
NRAS G12D
|
AML
|
PD98059 Sensitive: D – Preclinical
|
PD98059 Sensitive: D – Preclinical
|
NRAS G12D
|
CMML
|
NRAS G12D
|
CMML
|
selumetinib Resistant: D – Preclinical
|
selumetinib Resistant: D – Preclinical
|